Peimanfard, S.; Zarrabi, A.; Trotta, F.; Matencio, A.; Cecone, C.; Caldera, F.
Developing Novel Hydroxypropyl-β-Cyclodextrin-Based Nanosponges as Carriers for Anticancer Hydrophobic Agents: Overcoming Limitations of Host–Guest Complexes in a Comparative Evaluation. Pharmaceutics 2022, 14, 1059.
https://doi.org/10.3390/pharmaceutics14051059
AMA Style
Peimanfard S, Zarrabi A, Trotta F, Matencio A, Cecone C, Caldera F.
Developing Novel Hydroxypropyl-β-Cyclodextrin-Based Nanosponges as Carriers for Anticancer Hydrophobic Agents: Overcoming Limitations of Host–Guest Complexes in a Comparative Evaluation. Pharmaceutics. 2022; 14(5):1059.
https://doi.org/10.3390/pharmaceutics14051059
Chicago/Turabian Style
Peimanfard, Shohreh, Ali Zarrabi, Francesco Trotta, Adrián Matencio, Claudio Cecone, and Fabrizio Caldera.
2022. "Developing Novel Hydroxypropyl-β-Cyclodextrin-Based Nanosponges as Carriers for Anticancer Hydrophobic Agents: Overcoming Limitations of Host–Guest Complexes in a Comparative Evaluation" Pharmaceutics 14, no. 5: 1059.
https://doi.org/10.3390/pharmaceutics14051059
APA Style
Peimanfard, S., Zarrabi, A., Trotta, F., Matencio, A., Cecone, C., & Caldera, F.
(2022). Developing Novel Hydroxypropyl-β-Cyclodextrin-Based Nanosponges as Carriers for Anticancer Hydrophobic Agents: Overcoming Limitations of Host–Guest Complexes in a Comparative Evaluation. Pharmaceutics, 14(5), 1059.
https://doi.org/10.3390/pharmaceutics14051059